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Comparable to Alzheimer’s disease, mild cognitive impairment in Parkinson’s disease (PD-MCI) is associated with an increased
risk for dementia. However diﬀerent definitions of PD-MCI may have varying predictive accuracy for dementia. In a cohort of
101 nondemented Parkinson patients who underwent neuropsychological testing, the frequency of PD-MCI subjects and PD-
MCI subtypes (i.e., amnestic/nonamnestic) was determined by use of varying healthy population-based cut-oﬀ values. We also
investigated the association between defined PD-MCI groups and ADL scales. Varying cut-oﬀ values for the definition of PD-MCI
were found to aﬀect frequency of PD-MCI subjects (9.9%–92.1%) and, maybe more important, lead to a “shift” of proportion
of detected PD-MCI subtypes especially within the amnestic single-domain subtype. Models using a strict cut-oﬀ value were
significantly associated with lower ADL scores. Thus, the use of defined cut-oﬀ values for the definition of PD-MCI is highly
relevant for comparison purposes. Strict cut-oﬀ values may have a higher predictive value for dementia.
1. Introduction
Parkinson’s disease (PD) is increasingly recognized as a mul-
tidimensional disorder compromising motor but also a wide
range of nonmotor features, including cognitive functions
[1–3]. There is evidence that already a slight deterioration of
cognition may enhance the risk of conversion to dementia in
PD [4, 5]. However, not all PD patients with such a cognitive
profile develop dementia (PDD), and early identification
of these patients with particularly increased risk is still
not possible with suﬃcient accuracy [5–7]. Therefore, a lot
of eﬀort has been put on the identification of a clinical
risk profile and especially in the characterization of mild
cognitive deficits in patients who are later on developed
dementia [8].
The current classification of mild cognitive impairment
(MCI) in PD (PD-MCI) refers to the classification of
Petersen and coworkers [9]. Here, the cognitive profile of
MCI is basically defined by (i) the number of domains
aﬀected (single-/multiple-domain MCI) and (ii) the involve-
ment of memory function (amnestic/nonamnestic MCI).
Thus, for PD-MCI diagnosis, one needs to consider two
main aspects. First, assessments covering all relevant cog-
nitive domains associated with PD must be included in a
considerable test battery. Therefore, the Movement Disorder
Society (MDS)Task Force recommended neuropsychological
tasks for the assessment of major areas of subcorticofrontal
and cortically mediated functions [10]. Second, a cut-
oﬀ value to define cognitive impairment leading to the
diagnosis of PD-MCI must be defined. In previous studies,
dealing with this topic, diﬀerent cut-oﬀ values (−1, −1.5,
or −2 standard deviations (SD)) below the mean of a
healthy control group have been used to classify a cognitive
test performance as relevantly impaired [11–13]. In large
cohorts, this means that deficits occur in less than 16%
(−1 SD), 7% (−1.5 SD), or 2% (−2 SD) of the subjects in
the healthy population. Presently, a single test performance
of −1.5 SD below the population mean is increasingly
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accepted as the best cut-oﬀ value for PD-MCI [8, 14]. So
far, it is not known whether this cut-oﬀ value has a high
predictive value for PDD. In research studies, standard scores
could be determined to assess individual neuropsycho-
logical performance delineating specific cognitive domains
[8]. However, this method is not easy to implement in
clinical praxis due to the lack of appropriate reference
groups which are necessary for the evaluation of cognitive
performance over a repertory of neuropsychological tasks.
For clinical purpose, one rather needs to define how many
tests characterize one cognitive function and to what degree
this function needs to be aﬀected to make the diagnosis
of PD-MCI. Therefore, to define a cut-oﬀ value for PD-
MCI for clinical use, the level of impairment in both a
single test as well as within a cognitive domain has to be
considered.
The clinical profile of PD-MCI patients who are sup-
posed to be at higher risk for PDD has been investigated
in various studies, but these studies diﬀer regarding the
cut-oﬀ values used to define PD-MCI [12, 15–17]. Besides
the fact that it is not known yet which PD-MCI subjects
have the highest risk for conversion to PDD, it is not
evaluated whether the choice of diﬀerent cut-oﬀ values
might have an impact on the interpretation of the PD-MCI
phenotype.
The aim of this study was twofold: first, to compare
the frequency of PD-MCI and subtypes of PD-MCI by
use of varying cut-oﬀ values, and second, to analyse how
this variation of cut-oﬀ values might aﬀect the interpre-
tation of the clinical profile investigated in the PD-MCI
group.
2. Methods
2.1. Subjects. A nondemented group of 107 patients with
idiopathic PD according to the UKPD Brain Bank criteria
[18] was recruited from the Outpatient Clinic of the
Department of Neurodegenerative Disorders, University of
Tuebingen. Only patients older than 50 years, with adequate
or corrected hearing/visual abilities and German as mother
tongue, were investigated. Exclusion criteria were other
neurological diseases aﬀecting the central nervous system,
prior surgery for PD and a Mini-Mental State Examination
(MMSE [19]) score < 26, to exclude patients with possible
dementia [8]. In addition, exclusion of patients with higher
MMSE scores but diagnosis of probable dementia based on
level II criteria of the MDS Task Force [10] was made. Hence,
six patients with a performance (i) below a standard (z) score
of −1.5 in at least two of the following cognitive domains:
attention, executive functions, praxis and perception, mem-
ory or fluency, and naming abilities, (ii) self-report of
cognitive decline with insidious onset and slow progression,
and (iii) self-reported significant impact on instrumental
activities of daily living functions fulfilling the recommended
MDS dementia criteria were further excluded from data
analysis [14, 20]. The data sets of 101 nondemented PD
patients were analyzed. The study was approved by the
Local Ethical Committee, and all participants gave written
informed consent.
2.2. Neuropsychological Assessment. Cognitive and motor
assessments were carried out on medication. Neuropsycho-
logical testing was conducted within two weeks of motor
assessment. A comprehensive test-battery was composed to
assess the major areas of subcorticofrontal and cortically
mediated functions known to be aﬀected in PD [10]. Dif-
ferent domains were theoretically specified and, composition
was evaluated by internal consistency analysis. Cronbachs
alpha coeﬃcients indicated moderate to high consistency
structure of the scales (0.52 ≤ Cronbachs α-coeﬃcent ≤
0.86), except for the attention domain (−0.33). For the
attention domain, the Go-Nogo condition as well as the
Alertness test, which are commonly used paradigms to
assess diﬀerent aspects of attention, were applied [21]. Two
memory domains (list learning and memory recall, logical
memory) and four nonmemory domains were defined (see
below and Table 1 for details).
The domain “Executive function” (5 test scores) was
assessed as follows: planning ability was tested by the
Tower of London (TL-D) test [22], the trail-making test
B [23], and the figure test of the NAI- (Nuernberger
Altersinventar-) quantified set-shifting and set-maintenance
abilities [23]. Working memory performance was assessed
by the digit span part (forward and backward) of the
NAI [24]. Ideomotor apraxia (primarily characterized by
spatial postural and movement errors) is reported even in
nondemented PD patients [25]. This symptom is known
to be also caused by frontal lobe dysfunction [26, 27]. In
corticobasal degeneration, rather frontal lobe damage than
parietal or temporal lobe damage is proposed to account
for this symptom [28]. In our cohort, performance in the
ideomotor part of the Berlin-Apraxia test (BAXT) [29] was
found to be predominately associated with tests measuring
executive function.
Performance in the domain “attention” (2 test scores) was
recorded by using the subtests “Alertness” and “Go-Nogo” of
the test for attentional performance (TAP) [30]. The value
of phasic alertness expressing the subject’s ability to increase
attention processes in expectation of important stimuli and
the median reaction time for the Go-Nogo test was analyzed.
The domain “Praxis and visual function” was investigated
by 3 test scores: two praxis subtests of the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) [23],
that is, copying of line drawings and the delayed recall of
these drawings, as well as the object decision part of the
Visual Object and Space Perception Battery [31].
The trail-making test (TMT) part A [23], the Boston
Naming Test, and the semantic verbal fluency part of the
CERAD were used to cover the domain “psychomotor speed
and naming ability.” This test composition showed an accept-
able internal consistency structure, and imaging studies
support the assumption of a partly overlapping functional
brain network activated by the tasks included [32, 33].
The memory domain “list learning and memory recall”
was evaluated using three test scores of the German version
of the CERAD [23], word-list memory, word-list recall after
delay, word-list recognition, and the amount of incorrect
responses concerning the word list memory recall (word-list
intrusion).
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Table 1: Overview of the cognitive domains.
Nonmemory domains Memory domains
Executive function Attention
Praxis and
visual function
Psychomotor
speed and
naming ability
List learning and
memory recall
Logical
memory
Trail making test, part B 63.2 ± 35.1
Tower of London test 47.4 ± 26.4
NAI: Digit span 60.4 ± 30.0
NAI: Figure test 58.6 ± 22.5
Berlin Apraxia test 37.5 ± 4.1
TAP: Value of phasic alertness 49.7 ± 29.2
TAP: Go-Nogo, median RT 48.9 ± 32.1
CERAD: Constructional praxis 46.3 ± 33.8
CERAD: Constructional praxis
delayed recall
42.7 ± 36.6
VOSP: Object decision 49.7 ± 29.1
CERAD: Verbal fluency 44.1 ± 27.6
CERAD: Boston Naming Test 55.5± 31.5
Trail-making test, part A 56.9 ± 32.3
CERAD: Word-list memory 36.4 ± 26.5
CERAD: Word-list recall 41.6 ± 28.8
CERAD: Word-list recognition 48.6 ± 33.4
CERAD: Word-list intrusion 48.5 ± 31.6
WMS-R: Logical memory I 31.8 ± 28.9
WMS-R: Logical memory II 33.0 ± 27.9
Cronbachs alpha coeﬃcient 0.52 −0.33 0.61 0.58 0.72 0.86
All values are given as mean percentile rank scores ± standard deviation, except for the Berlin Apraxia test for which raw values are presented. CERAD:
Consortium for the Registry for Alzheimer’s Disease, German version; WMS-R—Wechsler Memory Scale: revised; NAI—Nuernberger Alters Inventar;
VOSP—Visual Object and Space Perception Battery; TAP—Testbatterie zur Aufmerksamkeitspruefung; RT—Reaction time.
The memory domain “Logical memory” (2 test scores)
was assessed by the logical memory I and II of the Wechsler
Memory Scale—Revised [34].
German norm data (percentile rank scores, PR) provided
in the test manuals of the neuropsychological assessments,
referring to an age-matched healthy population corrected for
age or both age and education (CERAD, TAP, TMT, and
TL-D), were used to compare test performance, except for
the BAXT. For the BAXT tests, information of the PR was
not available, but mean and SD of an age-matched healthy
control group was available, so that a standard score could be
calculated [29].
2.3. Neurological Scales. Neurological assessment included
the Hoehn and Yahr stage, the Unified Parkinson Disease
Rating Scale motor part (UPDRS-III) [35], and patient’s
history of medication.
2.4. Nonmotor Symptoms and Activities of Daily Living
Function. The Neuropsychiatric Inventory (NPI), which
evaluates diﬀerent behavioural domains (e.g., delusions, hal-
lucinations, depression, and apathy), was used for evaluation
of psychiatric disturbances [36]. The NPI total score was
applied to investigate the severity of abnormal behaviour.
The Parkinson’s Disease Questionnaire—PDQ-39 [37] and
the Beck Depression Inventory (BDI) [38] served as self-
rating scales measuring health-related quality of life and
mood.
The Nuernberger-Alters-Alltagsaktivita¨ten-Skala (NAA),
a patient 15-item self-questionnaire focussing on diﬀerent
aspects of the activities of daily living (ADL) functions
that is management of the financial situation and social
independence, was performed. In addition,its equivalent
was also assessed from the caregivers (Nuernberger-Alters-
Beobachtungsskala, NAB) [24].
2.5. Definition of PD-MCI. Standard (z) scores of −1, −1.5,
and −2 were defined as cut-oﬀ values for the definition
of PD-MCI. These cut-oﬀ values indicate that less than
16% (z < −1), 7% (z < −1.5), or 2% (z < −2) of the
healthy population score was below these criteria. We also
diﬀerentiated whether a subject scored low in at least 1 (oneT)
or at least 2 test scores (twoT) per cognitive domain. The six
resulting diagnostic criteria (z < −1oneT, z < −1.5oneT, z <
−2oneT, −z < 1twoT, z < −1.5twoT, and z < −2twoT) were
then applied to identify the frequency of PD-MCI subjects
within the cohort. We specified cut-oﬀ values of a varying
continuum, some of which are supposed to be more liberal
(z < −1oneT), and some being assumed to be more strict
(z < −2twoT) as diagnostic criteria for PD-MCI. Patients with
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Table 2: Percentage (including 95% confidence interval, 95% CI) of Parkinson patients with minimal cognitive impairment (PD-MCI) and
without (PD-noMCI) in regard to varying cut-oﬀ values.
PD-noMCI PD-MCI
N % 95% CI N % 95% CI
One test per domain below cut-oﬀ
z < −1 8 7.9 3.7–15.5 93 92.1 84.5–96.2
z < −1.5 28 27.7 19.5–37.7 73 72.3 62.3–80.5
z < −2 67 66.7 56.2–75.3 34 33.7 25.2–43.3
Two tests per domain below cut-oﬀ
z < −1 44 43.6 33.8–53.9 57 56.4 46.2–66.2
z < −1.5 70 69.3 59.3–77.9 31 30.7 22.1–40.8
z < −2 91 90.1 82.1–94.9 10 9.9 5.1–17.9
PD-MCI were further classified into one of the following four
subtypes: (1) amnestic single-domain PD-MCI (aﬀection
of one of the two memory domains); (2) nonamnestic
single-domain PD-MCI (aﬀection of one of the four non-
memory domains); (3) amnestic multiple-domain PD-MCI
(aﬀection of at least two domains including one memory
domain); or (4) nonamnestic multiple-domain MCI (aﬀec-
tion of at least two domains excluding memory domains)
[39].
2.6. Statistics. Frequencies of PD-MCI patients and PD-
MCI subtypes are reported as proportion of patients with
impairment in any cognitive domain referring to each of
the six diagnostic scores, including 95% confidence intervals
(95% CI; Vassar online program, http://faculty.vassar.edu/
lowry/VassarStats.html) [8]. Performance in the demograph-
ical (e.g., age) data are descriptively shown with median
and range. Post hoc explorative analysis of PD-noMCI
and PD-MCI groups referring to clinical data (e.g., motor
performance) were computed with nonparametric statistics,
for example, Mann-Whitney U test or χ2 test (e.g., gender).
Diﬀerences were assumed to be significant at P < .05 (two
sided). Statistical analyses were done with SPSS 17.0 for
Windows (SPSS Inc, Chicago, ILL, USA).
3. Results
3.1. Patients’ Characteristics. Median age of all 101 patients
was 67 (51–79) years, and 60 (59.4%) patients were
males. Median disease duration was 5 years (0.3–19 years).
Sixty-one volunteers (60.4%) received both levodopa and
dopamine agonists, 12 (11.9 %) were treated with levodopa
alone, 22 (21.8%) with dopamine agonists alone, and
one (1.0%) with amantadine alone. Four patients (3.9%)
were treated with either levodopa or dopamine agonists in
combination with entacapone or amantadine. One subject
(1.0%) received no anti-Parkinsonian medication. Twenty-
five patients (24.8%) received antidepressants.
Mean performance of all patients for each test is reported
in Table 1. PD patients scored lowest on both logical memory
performance tests. In general, large standard deviations
indicate a heterogenic test performance.
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Figure 1: Distribution of both Parkinson’s disease patients with
mild cognitive impairment (PD-MCI, black bars) and without (PD-
noMCI, white bars) by use of varying diagnostic criteria. Cognitive
impairment was chosen to be present in less than 16% (z < −1),
7% (z < −1.5) (PR < 7), or 2% (z < −2) of healthy controls in at
least one or two tests per cognitive domain. This demonstrates that
the frequency of PD-MCI was highly influenced by the selection of
the cut-oﬀ values.
4. Frequency of PD-MCI
Nearly all patients (92.1%, 95%CI [84.5–96.2]) scored below
the most liberal cut-oﬀ value (z < −1oneT, see Table 2
for details). Ten patients (9.9%, 95% CI [5.1–17.9]) scored
below the strictest cut-oﬀ value (z < −2twoT). Frequency
of PD-MCI was highly influenced by the selection of the
classification criteria (Figure 1). In summary, the association
between the number of patients defined as PD-MCI was as
follows: the stricter a cut-oﬀ was defined (e.g., z < −2twoT),
the less patients were categorized as PD-MCI. However, there
was an overlap between the 95% CI of the defined PD-MCI
frequency by application of either of the following cut-oﬀs:
“z < −2oneT” (PD-MCI: 33.7%, 95% CI [25.2–43.2]) or “z =
−1.5twoT” (PD-MCI: 30.7%, 95% CI [22.1–40.8]) as well as
either “z < −1.5oneT” (PD-MCI: 72.3%, 95% CI [62.3–80.5])
or “z < −1twoT” (PD-MCI: 56.4%, 95% CI [46.2–66.2]).
Parkinson’s Disease 5
Table 3: Percentage (including 95% confidence interval, 95% CI) of Parkinson patients with minimal cognitive impairment (PD-MCI) and
without (PD-noMCI) in regard to diﬀerent PD-MCI subtypes.
Single Multiple
PD-MCI total Amnestic Nonamnestic Amnestic Nonamnestic
% 95% CI % 95% CI % 95% CI % 95% CI
One test per domain below cut-oﬀ
z < −1 93 9.7 4.8–18.0 16.1 9.6–25.5 68.8 58.3–77.8 5.4 2.0–12.7
z < −1.5 73 21.9 13.4–33.4 21.9 13.4–33.4 48.0 36.3–59.8 8.2 3.4–17.7
z < −2 34 41.2 25.1–55.2 41.2 25.1–55.2 11.8 1.0–21.1 5.8 3.8–28.4
Two tests per domain below cut-oﬀ
z < −1 57 36.8 24.8–50.1 12.3 5.5–24.3 43.9 31.0–57.6 7.0 2.3–17.8
z < −1.5 31 54.8 36.3–72.2 19.4 8.1–38.1 22.6 10.3–41.5 3.2 0.2–18.5.
z < −2 10 80.0 44.2–96.5 20.0 3.5–38.1 0 0.0–34.5 0 0.0–34.5
Thus, frequency of subjects having more severe cognitive
impairment in at least one test score tended to overlap with
the frequency of patients having less severe cognitive deficits
in at least two test scores per domain.
5. Characterization of PD-MCI Subtypes
The proportion of subjects defined as amnestic multiple-
domain PD-MCI tended to be higher when using a more
liberal classification cut-oﬀ value (z < −1oneT, 68.8% 95%
CI [58.3–77.8] of PD-MCI patients) compared to a more
stringent cut-oﬀ (z < −2twoT, 0% 95% CI [0.0–34.5] of PD-
MCI patients, see Table 3 for details).
In general, the frequency of amnestic PD-MCI subtypes
was more heterogeneous (amnestic single domain: 9.7%–
80.0%; amnestic multiple domain: 0.0%–68.8%) with regard
to varying cut-oﬀ values than the frequency of nonamnes-
tic subtypes (nonamnestic single domain: 12.3%–41.2%;
nonamnestic multiple domain: 0.0%–8.2%). Less subjects
tended to be classified as having nonamnestic multiple-
domain PD-MCI than amnestic multiple domain PD-MCI
irrespective of the chosen cut-oﬀ value. The ratio “frequency
of amnestic single-domain PD-MCI over frequency of
nonamnestic single domain PD-MCI” was highly influenced
using either one (e.g., z < −1oneT: amnestic single-domain
9.7% versus nonamnestic single-domain 16.1%) or two test
scores (e.g., z < −1oneT: amnestic single-domain 36.8% versus
nonamnestic single domain 12.3%) per domain to define
cognitive impairment.
6. Post Hoc Comparison of
PD-noMCI with PD-MCI
Results of the explorative post hoc mean group analysis
must be interpreted with caution due to variations of
sample size and number of comparisons which may lead to
compromising power.
The following cut-oﬀs: “z < −2oneT” (PD-MCI = 33.7%)
or “z < −2twoT” (PD-MCI = 9.9%) were associated with
higher PDQ-39 total score (P < .05) and with caregiver’s
perception of lowered patients ADL functions (NAB P <
.03). Lower values for the NAB total score within the
PD-MCI group could also be demonstrated by using “z <
−1.5oneT” (P = .03) or “z < −1twoT” (P = .08) as
diagnostic criteria for PD-MCI. In addition, self-reported
reduction of ADL function was only significantly associated
with PD-MCI (P = .02) when the strictest cut-oﬀ value was
applied (z < −2twoT). This shows that ADL function scores
were significantly associated withMCI occurrence only when
strict cut-oﬀ values were taken. Interpretation of diﬀerences
between PD-MCI and PD-noMCI patients related to the
following variables were influenced by using varying cut-oﬀ
values in our cohort: disease duration (z < −1twoT, P =
.009), MMSE score (z < −1.5oneT, P < .001; z < −2oneT, P =
.01; z < −1twoT, P < .001; z < −1.5twoT, P = .003), and
the BDI score (z < −1.5oneT, P = .006; z < −2oneT, P =
.03, z < −2twoT, P = .03). Thus, interpretation of group
diﬀerences concerning these variables did not seem to be
systematically related to the chosen cut-oﬀ value.
The interpretation of the following demographic/clinical
variables was independent of the cut-oﬀ values applied: male
gender, age at evaluation, age at onset, UPDRS-III motor
score, and the NPI total score (P > .05).
7. Discussion
In our nondemented PD cohort, both frequency and clin-
ical profile of PD-MCI patients were relevantly dependent
on the cut-oﬀ value used for the definition of cognitive
impairment. However, disparities in the evaluated number
of PD-MCI were not unexpected as they reflect divergent
levels of severity of neuropsychological test impairment.
It is interesting that, by use of the most liberal cut-oﬀ
value, nearly all (92%) of our nondemented PD patients
were defined as cognitively impaired, compared to less than
16% of subjects in the healthy population (by definition).
This result confirms previous findings demonstrating that
slight cognitive impairment is frequent in PD, aﬀecting also
patients at very early disease stages [13]. Severe cognitive
deterioration (reflected by z-scores < −2 in at least two
test scores per domain) was found in less than 10% of our
patients. In newly diagnosed PD patients, Williams-Gray and
colleagues [11] reported a prevalence rate of 62% of PD-MCI
after defining a value below 1 SD of the normative means
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in age and IQ-matched samples as “cognitively impaired.”
In contrast, Muslimovic and colleagues [13] used a value
of 2 SD below the normative mean of healthy controls and
found only 23.5% of PD patients to score below these cut-
oﬀ values in standardized cognitive tasks. Although other
variables such as age or education may have contributed to
the diﬀerence between these two studies, our data make it
intriguing that in particular the definition of the threshold
for MCI explains this large divergence in prevalence of PD-
MCI patients. This eﬀect was also seen in our cohort by using
either a more liberal or a more stringent criterion to define
PD-MCI. In addition, both authors used diﬀerent numbers
of neuropsychological test scores for the classification of
PD-MCI, which has been shown to also aﬀect prevalence
of PD-MCI as well as sample size and inclusion criteria
[20]. Recently, the authors of a multicentre study including
eight centres in Europe [8] evaluating the prevalence of PD-
MCI concluded that MCI is a common syndrome aﬀecting
about 25% of PD patients. In this study, a standard score
for each domain was calculated. Regarding our cohort, a
performance below a z-score of −1 in at least two test scores
per domain seems to be closest to the population-based
prevalence reported in this study. Results from our study lead
to the assumption that the application of diﬀerent diagnostic
criteria aﬀects the sensitivity of the detection of PD-MCI.
Comparing our data and data from other studies, one may
conclude that a unique PD-MCI profile does not exist.
Rather, studies using diﬀerent criteria for the classification
of PD-MCI seem to characterize subgroups in varying
disease stages of cognitive deterioration. Therefore, varying
studies may diﬀer concerning the clinical profile of PD-
MCI patients identified [4, 12]. Diﬀerent cut-oﬀ values may
primarily represent a continuous deterioration of cognitive
functions in our study population to which both severity
of errors and/or the number of cognitive scores aﬀected
may contribute. Therefore, it is intriguing to hypothesize
that deterioration within a cognitive domain is paralleled
by a spreading of cognitive dysfunction throughout other
cognitive domains. This hypothesis may oﬀer an alternative
model for the classification of mild to moderate cognitive
impairment in PD as cognitive dysfunction is known to
be heterogeneous in these patients [40]. According to our
findings, we suggest the use of neuropsychological test
batteries for future clinical or research application to (i)
define a unitary cut-oﬀ value and (ii) standardize how many
test scores within a cognitive domain need to be below this
defined cut-oﬀ value for the diagnosis of PD-MCI.
In our cohort, varying cut-oﬀ values for the definition
of PD-MCI not only aﬀect frequency of PD-MCI subjects
but, maybe more important, lead to a “shift” of the
proportion of detected MCI subtypes especially within the
amnestic single-domain subtype. Amnestic PD-MCI was
more frequent when we used more stringent criteria (i.e.,
if more than one test score was required to be below the
defined cut-oﬀ value for the diagnosis of PD-MCI). This
means that patients with more severe cognitive dysfunction
had an increased probability to suﬀer also from memory
dysfunction. Amnestic PD-MCI has already been described
to be a frequent syndrome in other studies [4, 12]. Based
on these finding, we conclude that for investigations dealing
with PD-MCI subtypes, rigorous classification standards
must be applied. The high frequency of amnestic MCI can
not be explained by the number of test scores used per
domain (it is suggestive that a higher number of scores
assessed per domain increases the probability to detect a
deficit), as we used a smaller number of test scores for the
diagnosis of amnestic PD-MCI than for the diagnosis of
nonamnestic PD-MCI (Table 1).
As limitation of the study presented here, it has to be
kept in mind that interpretation of the post hoc comparison
of PD-MCI and PD-noMCI patients must be taken with
caution as discrepancies of sample size may compromise
statistical power. Therefore, we may have not detected
diﬀerences in other variables known as potential risk markers
for dementia in PD such as demographical variables (e.g.,
age), motor performance and/or behavioural abnormalities
between PD-MCI and PD-noMCI patients [1]. However,
especially in our PD-MCI groups with smallest sample size,
we found the strongest eﬀect concerning to lower ADL
functions.
In summary, our data supports the suggestions that
a more liberal diagnostic criterion might be helpful for
investigating even subtle cognitive impairments or minor
changes in the course of PD. Application of a stricter
cut-oﬀ value might increase specificity and/or the positive
predictive value to detect patients at high risk for dementia.
This hypothesis, however, needs to be verified in future
longitudinal studies. A first corroboration of this hypothesis
may be derived from the fact that a relevant association of
both reduction of ADL function and lowered self-esteemed
health-related quality of life—both parameters are relevantly
associated with PDD [41] — was only observable in the PD-
MCI group that was classified by the strictest criterion. As, in
PD, cognitive dysfunction is most probably progressive [42];
we speculate that patients meeting the strictest criteria for
MCI will show a higher conversion rate to dementia within
a shorter time period. This hypothesis will be tested in an
ongoing longitudinal study.
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